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MEDICINE, TECHNOLOGY, AND GENETIC
ENGINEERING: REFLECTIONS FROM THE OUTSIDE
by
Jeffrey R. Plittman
Arkansas State University
Abstract
Advances in technology are producing many changes in the
ways humans view and manage their lives. The refinement of
genetic engineering techniques has created vast opportunities for
humankind, along with novel problems and dangers. Accordingly,
the questions that must be addressed pertain to the nature of life
itself. Yet the scientific community can not be given sole
discretion In managing todey's technologies. Instead, all segments
of society must be Involved In determining how genetic
engineering will be used.
Of all the areas of human endeavor, technology most often affects the
field of medicine. The marriage of technology and medicine - science
applied to the art of healing - influences persons in a manner unlike any
other type of scientific undertaking. Changes in the "technology of
medicine" come fast and furious, and usually involve questions concerning
the nature of death and sickness. Moreover, these questions have
more than academic significance to the public. Along with the benefits of
medical technology are, of course, problems to be addressed.
A growing number of critics claim the marriage of medicine and
technology Is not necessarily a match made in heaven. They feel changes
In technology are threatening society's moral foundation, destroying
person's perceptions ?f the meaning of life, and endangering the existence
of the human species.
Ethical questions in the medical field are prevalent, but certainly not
new. The answers to such querries can prove evasive and controversial.
For example, the issue of abortion has sparked bitter discussions. On
December 1, 1982 Mr. Barney Clark opened a new chapter of medical
history, with the first human use of an artificial heart. As a result of
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this development, questions about the quality and cost of life have
intensified.L However, one particular technology, with extensive
applications both within and outside the field of medicine, is giving rise to
questions that go beyond those already raised. Visions from Aldous
Huxley's-Brave New World are becoming realities through the technology
known as genetic engineering.
A Definitional Introduction
Genetic manipulation, genetic engineering, gene splicing, and gene
therapy are terms that conjure up vivid and sometimes horrifying mental
pictures. Genetics - the science of heredity - has been around for
sometime, but recent scientific advances have dramatically altered
its significance. To analyze the various societal issues involved with
todey's genetics, the basic scientific principles must be outlined and
defined.
Many of the domestic animals, crops, and plants In existence today are
human creations. They are the result of a selective breading pros
aimed at enhancing desired characteristics. This fairly innocuous
"genetic manipulation" has raised little outcry from the public. Of more
recent origin is "genetic engineering", a term that denotes a more active
intervention in the evolutionary process.3
All living organisms are composed of cells; the human body contains
billions of cells. Most cells share a common structural design, including
a nucleus that stores genetic information. Within the nucleus are pairs of
chromosomes. Each chromosome contains a long thread of
deoxyribonucleic acid, or DNA. DNA - the key to contemporary genetics -
has been called the "master molecule of life", as almost all living
organisms possess it (Judson, 1979). Portions of DNA contain coded
instructions which enable a cell to perform a particular function, e.g., to
manufacture a necessary protein. These DNA segments are called genes,
and they are central to understanding heredity. It is through genes that
the blueprint of life is passed from one organism to its offspring, from a
mother and father to their child. And it is on these genes the spotlight of
science and the heat of debate currently falls.
Genetic engineering refers to the genre of technology that utilizes a
range of procedures that add genetically determined characteristics to
cells that would not otherwise possess them, or would acquire these traits
only after many years of development. Gene splicing, a form of genetic
engineering, involves the technology of recombinant DNA. With this
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technique, sections of DNA can be removed from one chromosome and fused
with a chromosome of another cell. Thus DNA from different species can
be combined to create a new organism. Gene therapy is the use of gene
splicing to introduce a normal functioning gene into a cell that contains a
mutant or defective gene.
The Business of Genetic Enineering
Advanced Genetic Sciences, Genex, Agrigenetics, Cetus Madison, and
Genetech are not household names. Yet they are five of the largest
corporations Involved in the genetic engineering business. According to a
recent Department of Commerce (1984) report, several hundred U.S.
companies are now employing biotechnology (genetic engineering).
Present estimates of the total market for their products by the year 2000
range from 15 to 100 billion dollars.
Wall Street has not ignored the glamor and appeal of the new
technology companies. Genetech was formed in 1976 to utilize patented
recombinant DNA technology. In 1 980 Its initial stock offering set a Wall
Street record for the fastest rise in price per share, going from $35 to
$89 In 20 minutes. The following year, Cetus Corporation set a Wall
Street record for the largest amount of money raised in an initial
offering, or $115 million.
The biotechnology industry was spawned largely through government
expenditures. Over the last 30 years there has been growing federal
support for basic biomedical research. This support has created the
knowledge and personnel base that provides the foundation for current
blo-technical activities. The leading federal agency involved in research
has been the National Institute of Health (NIH). The NIH, consisting of I I
institutes and many programs, constitutes the world's largest biomedical
research laboratory. Its present budget of over $3.3 billion supports the
work of the Institute's 3000 scientists and 2000 laboratories. The NIH
spends 80 percent of its budget to support outside research at hospitals,
universities, and other laboratories.
The business of genetic engineering Is not without regulation.
Regulatory power over the biotechnology industry is possessed by at least
17 federal agencies.4 Which agency has jurisdiction depends on the
product manufactured or the research undertaken. For example, the Food
and Drug Administration (FDA) approves human drugs, diagnostics, and
food additives, while the Department of Agriculture has jurisdiction over
research conducted on plants and animals. The NIH Recombinant DNA
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Advisory Committee (RAC) has authority over basic research. Due to
overlapping jurisdiction, turf disputes between regulatory agencies can
create administrative delays. Approval of two products developed by
Genetech for use on cattle was delayed for over a year because of a
Jurisdictional dispute between the Department of Agriculture and the FDA
(Rhein, 1985). To ease potential conflicts, the Reagan Administration
has been attempting to define more clearly regulatory authority and
streamline the regulatory process.
Applications of the Art
On April 7, 1985 it was reported that researchers at the Cetus
Corporation had succeeded in splicing and cloning the human gene for the
protein tumor necrosis factor, or TNF (Jonesboro Sun, 1985). It is
hoped that this protein, produced naturally in the human body in small
quantities, can be used to attack malignant cancer cells while leaving
healthy tissue unharmed. The first human trials of TNF are expected to
begin in early 1986. The prospects for successful TNF use appear good,
although previous laboratory products (e.g., interferon - a
virus-fighting substance) have proved unsuccessful in stopping the
spread of cancer.
The Cetus Corporation's TNF is just the latest in a number of
increasingly frequent announcements of biotech breakthroughs. The
process began in the 1950s when James Watson and Francis Crick
discovered the structure of DNA. In the 1970s, when scientists first
succeeded In splicing foreign genes into a ring of DNA, genetic engineering
was underway.
Applications of genetic engineering are numerous, varied, and quite
amazing. A simple gene-spliced bacterium, when placed in a fermentation
broth, can produce more than a billion copies of itself In 15 hours. This
growth rate can be contrasted with, for example, the normal method of
insulin production. Prior to 1982, to supply diabetics in the U.S. with
insulin the pancreata of over 80 million cows and pigs were needed
yearly. In 1982, insulin produced via recombinant DNA methods was
approved for sale in the U.S. and Great Britain.
Products developed by using recombinant DNA techniques have
entered the marketplace In Increasing numbers over the last decade. The
following is a partial list of current recombinant DNA product areas:
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*vaccines - largely restricted to animal vaccines, although work
is nearly completed on a type designed to fight human cancers
associated with viruses;
*hormones - Including human Insulin, a growth hormone to fight
human dwarfism, and a growth hormone for cattle;
*bacteria - designed to protect plants from frost or crops from
damaging pests;
*enzymes - including rennet, used in making cheese.
The aforementioned applications of biotechnology, although obviously
noteworthy, have not stirred the same level of controversy as those which
relate to human medicine.
In the summer of 1980, Dr. Martin Cline attempted to cure two
persons suffering from thalassemia - a fatal blood disease related to
sickle-cell anemia - by inserting normal hemoglobin genes into these
patients' bone marrow. The surgery was not successful, having no effect
positive or negative. Moreover, the operations were performed In Italy
and Igrael, because approval for the surgical technique was denied in the
U.S ..As a result of Dr. Cline's activities, he was forced to resign as
Chief of Hematology/Oncology at UCLA, and lost two federal grants worth
more than $190,000 (Sun, 198 1 ).
The unsuccessful attempt at human gene therapy has renewed debate
regarding the technique. Potential applications of gene therapy in
humans abound. Single gene mutations, the first logical targets of gene
therapy, are known to cause as many as 2000 human disorders
(McKusick, 1982). A defect in just one gene - cells have as many as
100,000 genes - can have fatal consequences.
Existing traditional treatments of genetic disorders are aimed at
modifying or easing the damage caused by defective genes. Oene therapy Is
concerned with curing the disorders, not treating the symptoms. This is
accomplished through the Insertion of a normal gene Into the cell where
the defective one is active, therapy attempting to supplant the mutant
gene's activity. Gene surgery would take the additional step of surgically
removing a defective gene and Inserting a normal one in its stead.
Gene therapy, as discussed, would involve only alterations to somatic
cells, or those comprising parts of the body other than germ cells. The
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reproductive (sex) cells in humans, either sperm or egg, are the germ
cells. In theory, then, gene therapy would not affect a change in a
patient's offspring. A child would inherit characteristics, including
defects, independent of the performed therapy. The same gene therapy
performed on a parent would possibly be necessary for the parent's child.
One solution for this scenario would involve the most controversial of all
genetic technologies, which entails altering germ cells or fertilized eggs.
Several recent laboratory developments have involved genetic
manipulation of germ cells (Mark, 1981; Palmlter, Chen, and Brinster,
1982; Brlnster, et. al., 1981). In one experiment, fertilized mouse
eggs were injected with rabbit hemoglobin genes. The developed offspring
were reported to contain rabbit hemoglobin in their red blood cells
(Wagner, et. al, 1981). This approach could be applied to fertilized
human eggs through in vitro fertilization techniques.6 Accordingly,
human defects could be identified, Isolated, and corrected, all before the
child is "born". As the fetus develops it would not contain the mutant
genes nature otherwise would have provided.
Issus/Anahysis
The manufacture of pharmaceuticals and other products via
recombinant DNA technology is a reality.7 The NIH's recombinant DNA
Advisory Committee has Indicated recently that it might be ready to
approve gene therapy applied to human patients (Bishop and Waldholz,
1985). And experiments continue on the alteration of germ cells and
fertilized eggs of laboratory animals. These related, but distinct, areas of
technology are generating considerable debate. The following discussion
will Identify and examine some of the major questions being posed by
experts and laymen. The Issues surrounding genetic engineering fall into
two categories: those regarding unforeseen deleterious effects of the new
technologies, and ethical concerns that must be addressed even if the
techniques work as desired.
Examples of ill-advised human manipulation of the environment are
numerous. The kudzu vine, gypsy moth, and Dutch elm disease created
problems that could have been avoided with foresight. Chemical engineers
of the 1920s did not conceive of acid rain as a problem, while few
physicians in the 1940s were concerned about the effects of low-level
radiation exposure. And scientists, chemists, and product engineers today
are imperfect in their efforts to keep unsafe products and chemicals off
the market and out of food. Critics contend that genetic engineering is a
field of great uncertainty, since scientific research often leads into
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unanticipated areas. They conclude that a ban on experiments Is
necessary to protect society from unanticipated catastrophies.
The cited problems are real, but they do not support a ban on genetic
engineering. Despite past setbacks, scientific advances have impoved
greatly life over the past fifty years. Extensive government regulations
presently in place are very protective and restrictive. Furthermore,
problems with genetically engineered products over the last decade have
been nonexistent. After all, genetic engineering only accelerates a
process that occures randomly without human Intervention. In nature,
bacterial bits of genetic material commonly are transferred between
species.
Persons should not place their collective heads in the send when
recombinant DNA technology is applied. But the issue becomes a question
of burden of proof. Critics would require scientists to prove that their
procedures are completely safe before they proceed. Such proof is, of
course, rarely possible. Rather, the burden of proof must be placed on
those opposing genetic engineering. The potential benefits from
technologies such as recombinant DNA are enormous. And the scientific
community generally agrees the techniques are safe. To stop the advance
of knowledge, without first Identifying specific dangers, is undesirable
and unworkable.0
Of a different nature are concerns about "man" playing God. Humans
are composed of the same DNA molecules as all other living organisms.
Will persons lose their sense of self when they start manipulating the
building blocks of life? A line must be drawn between changes in somatic
cells and germ cells.
Gene therapy on somatic cells, replacing defective genes with normal
funtioning ones, is simply an extension of the surgical techniques
practiced for the last century. A defective portion of the body is repaired
or replaced, albeit through a very sophisticated surgery. Accordingly,
questions should focus on the effectiveness of gene therapy and not on Its
desirability as a medical technique. Regarding the notion of "man"
playing Cod, the following question is relevant: Is It God-like to deny
therapy to persons suffering greatly from sickle-cell anemia or cystic
fibrosis?9
An entirely different area of concern involves changes In germ cells
or fertilized eggs. One could ask whether it is better to remove mutant
genes from a germ cell, or wait until a child is born defective?
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Theoretically, it is better to avoid a problem. In practice, however, it
would be very difficult to identify and isolate defective genes at that stage.
And morally, there are many unanswered questions about such a
procedure.
For example, what is a defect? Are low intelligence and
unattractiveness defects? Should selection of hair color or body size be
allowed If this were possible? Would Beethoven have been a better
person and musical composer If his hearing and eyesight problems had
been genetically corrected before birth? These questions are difficult,
and a consensus on appropriate answers is lacking. Near perfect chances
for success would be required before genetic surgery could be attempted.
Society would not accept an 80 or 90 percent success rate on the
manipulation of germ cells, for such surgery could possibly damage
unborn children.
Conclusion
Over the last several decs, humankind has been obliged to reconcile
the desire for knowledge with the survival of the human species. With
advances in knowledge, persons now have the ability to either destroy
themselves or provide beneficial services for society. If properly
applied, the science of genetics will fall into the latter category, thereby
offering a great tool for human betterment.
Yet scientists must be concerned constantly with potential pathogens,
or those organisms that could be converted, with a few mutations, from
something harmless to a serious menace. But scientists are properly
cautious, due in large part to elaborate government regulations. The
probability of major unintentional damage being inflicted upon
humankind through genetic engineering is very small. Intentional
misuses of genetic technology are probable, as the world will always
produce a number of Hitlers. However, the fear of potential abuse alone
should not stop the pursuit of beneficial knowledge and technologies.
The issue surrounding the genetic alteration of germ cells, or
fetilized eggs, has a different character. The profound nature of gene
splicing, as applied to unborn individuals, requires the attention of all
citizens. This is particularly important because present regulatory
efforts in this area are not sufficient. The whole of society, not just
scientists and administrators, must be involved in deciding how this
technology shall be used. Public education efforts should be increased,
while a committee with oversight authority should be convened. This
committee would draw membership from scientists, religious and
academic leaders, lawyers, doctors, and members of the general public.
For now that humankind has the tools of science, they must not be used to
destroy the world.
Most important is that humans must not become enamored by
technology to the extent that moral and ethical questions are obscured.
Nowadays the tendency is to move ahead with programs simply because
they are technologically possible. Technology, in other words, cannot
answer questions that only humans can pose. For at the root of technology
is human action that cannot be obscured if this tool is to be used correctly.
FOOTNOTES
1. Humankind has always struggled with, and at times fought against,
advances in technology. The issues addressed by this paper, though,
represent a leap from issues raised by previous changes in knowledge.
Challenges to the medical technologies of 1985 cannot be attributed
solely to humankind's inherent resistance to change.
2. Prior to Mr. Clark's operation, the federal government had spent over
$200 million aiding research in the development of artificial
(mechanical) heart technology. To purchase an artificial heart,
$1 00,000-$200,000 is needed for the operation and first year service
alone. These facts, and others, give rise to a number of areas of
controversy, including the following:
*Should an artificial heart be denied to a patient based on his or
her ability to pay? The taxpayer has already funded a portion of
his/her bill by contributing to the research vis-a-vis tax
payments.
*Should any life-giving technology be denied a patient based on
financial considerations? When the dialysis machine became a
perfected technology, treatment was partially restricted to those
able to bear the costs involved. This restriction has all but
disappeared. Will the same evolutionary process affect new
medical technologies and, if so, where will the money be found to
pay for the treatment provided?
1.38
3. The term "genetic engineering" was first used by Rollin D. Hotchkiss,
"Portents for a Genetic Engineering," 56 J. Heredity 197 (1965).
4. For a listing of the federal agencies, and a description of their powers
and areas of authority, see the President's Commission for the Study of
Ethical Problems in Medicine and Biomedical and Behavioral Research:
pllclng Life, The Social and Ethical Issues of Genetic Engineering with
Human Beins, U. S. Government Printing Office, Washington, DC, 1982.
5. Approval was denied, among other reasons, on the basis that more
animal work was needed. See the President's Commission for the Study of
Ethical Problems in Medicine and Biomedical and Behavioral Research:
Protecting Human Subjects. U.S. Government Printing Office, Washington
(1981)at 177, 182.
6. The approach would involve the following: (1) isolating and
amplifying the desired gene by standard recombinant DNA techniques;
(2) removing a mature ovum from a woman and fertilizing it in vitro;
(3) injecting copies of the cloned gene into the fertilized egg (zygote)
using microsurgical techniques; and (4) Implanting the genetically
altered zygote into the woman's uterus.
7. Users of recombinant DNA techniques won a significant legal battle
when the Supreme Court ruled patent protection was available for new
life forms created. Diamond v. Chakrabarty 447 U.S. 303, 316
(1980).
8. Genetic engineering on biological warfare weapons isa separate Issue.
Drawing on recombinant DNA technology, biological weapons could
conceivably be devised to eliminate selected animals, plants, or people.
Despite the 1972 Biological Weapons Convention, this type of research is
probably being conducted in the Soviet Union, United States, and
elsewhere. Research in this area is reprehensible and should be stopped.
But the problem is with the misuse of knowledge, not with the scientific
knowledge Itself. A ban on all genetic engineering in the U.S. would not
stop such efforts elsewhere in the world.
9. There is considerable support from religious scholars for gene
therapy, appropriately applied. Pope John Paul II gave his approval for
genm splicing when its aim is to ameliorate the conditions of those who are
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affected by chromosomic diseases. "La sperimentozione in biologia deve
contribuire al bene integrale dell'uomo," L'Osservatnre Romano, Rome,
Oct. 24, 1982, at 2.
10. Near perfection for the surgical procedure would not be required if
the following conditions could be met:
* It was ascertainable with near certainty, upon examination of the
fertilized egg, the child would be born with a serious defect;
* The genetic surgery would, at worse, not improve the child's
condition - it would not further damage the unborn child.
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